Nestle Acquires Aimmune For $34.50 Per Share In Cash Or $2.6B

Aimmune Therapeutics announced that it has entered into a definitive agreement for Societes des Produits Nestle to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted equity value of $2.6B.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.